Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2020

View Archived Issues

Metformin, explained

Autolus presents phase I data from Amelia study of AUTO-3 in pediatric patients

Phase I data presented for ambrisentan in sickle cell disease

PGC-1alpha as a novel therapeutic target in sickle cell disease

CD137 deficiency linked to susceptibility to EBV-associated lymphoma

Repotrectinib reduces tumor growth of ALK-driven neuroblastoma

Spot on: Breaching all three meninges improves drug delivery to brain

Ono presents phase II data for tirabrutinib in relapsed/refractory Waldenstrom's macroglobulinemia

Herantis advances xCDNF program into lead optimization

China NMPA approves Cecolin HPV16/18 vaccine

Amgen patents KRAS mutant inhibitors

New compounds for hepatitis B virus presented by VenatoRx Pharmaceuticals

Ryvu Therapeutics identifies hSTING receptor agonists

Pfizer divulges new GLP-1R agonists

Roche identifies new TLR7/8/9 antagonists

Regeneron begins open-label extension study with REGN-3918 in PNH

Genmab studies GEN-1042 safety for malignant solid tumors in phase I/IIa trial

Roche starts phase I study of RO-7296682 in advanced solid tumors

GSK initiates phase III study of belantamab mafodotin for newly diagnosed multiple myeloma

U.S. researchers present novel coagulation factor VIIa chimera for hemophilia patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...